TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06032923: Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 78 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT06032923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06032923 Rescue Dossier →